|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.
|
20932324 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.
|
20932324 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Nkx3.1 is a putative prostate tumor suppressor that is expressed exclusively in the prostate under the regulation of androgen, and p27(KIP1) functions as a cell proliferation inhibitor and apoptosis trigger by disrupting the cyclin-dependent kinase (CDK)-cyclin complex.
|
19266349 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.
|
18691549 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype.
|
18583941 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
CDKN1B V109G polymorphism frequency and prostate cancer risk in Taiwan.
|
18645269 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
|
17319789 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
|
17404436 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
|
16097446 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
|
15798096 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.
|
15026335 |
2004 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.
|
12727815 |
2003 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.
|
12727815 |
2003 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.
|
12727815 |
2003 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
|
12188931 |
2002 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
|
12429629 |
2002 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The first describes mapping and cloning of a new candidate gene, ELAC2, whereas the second demonstrates how cooperation between Cdkn1b and Pten contribute to suppression of prostate tumors.
|
11175773 |
2001 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Together, these data implicate increased AKT activity in prostate tumor progression and androgen independence and suggest that diminished p27(Kip1) expression, which has been repeatedly associated with prostate cancer progression, may be a consequence of increased AKT activity.
|
10827191 |
2000 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicate that frequent loss of the cyclin-dependent kinase inhibitor p27(Kip1) in human prostate cancer cells correlates with advancing histological aggressiveness, implicating deregulation of p27(Kip1) in prostate tumor progression.
|
9815624 |
1997 |